Regeneron
1Q Revenues: $1.7 billion (+13%)
1Q Earnings: $461.1 million (-4%)
Comments: EYLEA Injection U.S. sales increased 9% to $1.1 billion. EYLEA sales outside the U.S., recorded by the company’s collaborator Bayer, increased 7% to $669 million. Global Dupixent sales, which are recorded by the company’s collaborator Sanofi, were $374 million. Libtayo U.S. sales were $27 million in the quarter; Libtayo was launched in October 2018.